HEALTHCARE PROVIDER RESOURCES
XARELTO® REPRINTS
REDUCING STROKE RISK IN NONVALVULAR ATRIAL FIBRILLATION (NVAF)
Patel MR et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Post-marketing Safety Surveillance Study
Tamayo S et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27,467 patients taking rivaroxaban
Bansilal S et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)
ROCKET AF Subgroup: Moderate Renal Impairment
Fox KAA et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
End-stage Renal Disease (ESRD)
Dias C et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis
ROCKET AF Subgroup: Previous Stroke or Transient Ischaemic Attack
Hankey GJ et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF
ROCKET AF Subgroup: Heart Failure
van Diepen S et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF
Halperin JL et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET AF trial
Meta-analysis of Real-world Evidence
Coleman I et al. Meta-analysis of real-word evidence comparing non-vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) TREATMENT AND RISK REDUCTION
The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism
The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
Prins MH et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN–DVT and PE randomized studies
EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism
Ageno W et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study
Prins MH et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE)
DEEP VEIN THROMBOSIS (DVT) PROPHYLAXIS AFTER KNEE OR HIP REPLACEMENT SURGERY
Eriksson BI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
Kakkar AK et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lassen MR et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
Turpie AGG et al. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment
CORONARY ARTERY DISEASE (CAD) AND PERIPHERAL ARTERY DISEASE (PAD)
Eikelboom JW et al. Rivaroxaban with or without aspirin in stable cardiovascular disease
Connolly SJ et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
Anand SS et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
RESOURCES TO HELP YOUR PATIENTS
Janssen CarePath Savings Program
For eligible patients with commercial insurance and an approved chronic condition.
A helpful medication and appointment tracking and reminder tool designed to empower users to take an active role in their own health care.
PROFESSIONAL RESOURCES
Janssen MD® Professional Information Resource
Access to scientific and clinical information and services for Janssen products, including XARELTO®.
Meta-analysis of Real-world Evidence
Coleman I et al. Meta-analysis of real-word evidence comparing non-vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
OTHER RESOURCES
◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.